INSMED INC Interest Expense Nonoperating
INSMED INC (INSM) reported Interest Expense Nonoperating of $20.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- INSMED INC interest expense nonoperating for the quarter ending 2026-06-30 was $20.27M, a 4.58% decline year-over-year.
- INSMED INC interest expense nonoperating for the quarter ending 2026-03-31 was $20.08M, a 6.89% decline year-over-year.
- INSMED INC interest expense nonoperating for the quarter ending 2025-12-31 was $20.60M, a 4.41% decline year-over-year.
- INSMED INC interest expense nonoperating for the quarter ending 2025-09-30 was $20.38M, a 3.19% decline year-over-year.
- INSMED INC interest expense nonoperating for fiscal 2025 was $83.80M, a 1.32% decline from fiscal 2024.
- INSMED INC interest expense nonoperating for fiscal 2024 was $84.91M, a 3.94% increase from fiscal 2023.
- INSMED INC interest expense nonoperating for fiscal 2023 was $81.69M, a 208.91% increase from fiscal 2022.
- INSMED INC interest expense nonoperating for fiscal 2022 was $26.45M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.27M 10-Q · filed 2026-08-06 | $40.35M 10-Q · filed 2026-08-06 | $60.95M derived: sum of 3 quarters · filed 2026-08-06 | $81.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.08M 10-Q · filed 2026-05-07 | $40.68M derived: sum of 2 quarters · filed 2026-05-07 | $61.06M derived: sum of 3 quarters · filed 2026-05-07 | $82.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $40.98M derived: sum of 2 quarters · filed 2026-02-19 | $62.23M derived: sum of 3 quarters · filed 2026-08-06 | $83.80M 10-K · filed 2026-02-19 |
| 2025-09-30 | $20.38M 10-Q · filed 2025-10-30 | $41.63M derived: sum of 2 quarters · filed 2026-08-06 | $63.20M 10-Q · filed 2025-10-30 | $84.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.25M 10-Q · filed 2026-08-06 | $42.81M 10-Q · filed 2026-08-06 | $64.36M derived: sum of 3 quarters · filed 2026-08-06 | $85.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $21.57M 10-Q · filed 2026-05-07 | $43.12M derived: sum of 2 quarters · filed 2026-05-07 | $64.17M derived: sum of 3 quarters · filed 2026-05-07 | $85.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $21.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $42.60M derived: sum of 2 quarters · filed 2026-02-19 | $63.87M derived: sum of 3 quarters · filed 2026-02-19 | $84.91M 10-K · filed 2026-02-19 |
| 2024-09-30 | $21.05M 10-Q · filed 2025-10-30 | $42.32M derived: sum of 2 quarters · filed 2025-10-30 | $63.36M 10-Q · filed 2025-10-30 | $84.15M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $21.27M 10-Q · filed 2025-08-07 | $42.31M 10-Q · filed 2025-08-07 | $63.09M derived: sum of 3 quarters · filed 2026-02-19 | $83.38M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $21.04M 10-Q · filed 2025-05-08 | $41.83M derived: sum of 2 quarters · filed 2026-02-19 | $62.11M derived: sum of 3 quarters · filed 2026-02-19 | $82.73M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $20.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $41.07M derived: sum of 2 quarters · filed 2026-02-19 | $61.69M derived: sum of 3 quarters · filed 2026-02-19 | $81.69M 10-K · filed 2026-02-19 |
| 2023-09-30 | $20.29M 10-Q · filed 2024-10-31 | $40.91M derived: sum of 2 quarters · filed 2024-10-31 | $60.91M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $20.62M 10-Q · filed 2024-08-08 | $40.62M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $26.45M 10-K · filed 2025-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |